

VERSION WITH MARKINGS TO SHOW CHANGES MADE

1. (Amended) A method of [treating a mammal having] reducing cerebral edema in a mammal, comprising [a)] administering to said mammal [an effective amount of] a hVEGF antagonist in an amount effective to reduce the volume of cerebral edema in the brain of the mammal, wherein said antagonist comprises an anti-hVEGF antibody[; and
b) determining the degree of cerebral edema; whereby the hVEGF antagonist reduces cerebral edema].
8. (Amended) The method of claim 1 wherein said anti-hVEGF antibody [comprises a chimeric murine antibody wherein at least one constant chain domain is replaced by the homologous human sequence] consists of murine variable domains and human constant domains.
9. The method of claim 1 wherein said anti-hVEGF antibody comprises a humanized antibody.
10. The method of claim 1 wherein said antibody comprises a monoclonal antibody.